Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: To compare the antiviral efficacy of adefovir (ADV) in lamivudine (LMV)-resistant patients with LMV treatment in nucleoside-naïve patients, using serum samples collected sequentially during the course of treatment progressing from LMV to ADV. Methods: Forty-four patients with chronic hepatitis B (CHB) were included. The patients were initially treated with LMV and then switched to ADV when LMV resistance developed. Antiviral efficacy was assessed by measuring the following: reduction in serum HBV DNA from baseline, HBV DNA negative conversion (defined as HBV DNA being undectable by the hybridization assay), and HBV DNA response (either HBV DNA level 105 copies/mL or a 2 log10 reduction from baseline HBV DNA level). Results: After two and six months of treatment, HBV DNA reduction was greater with LMV compared to ADV treatment (P = 0.021). HBV DNA negative conversion rates were 64% and 27% after one month of LMV and ADV treatment respectively (P = 0.001). Similarly, HBV DNA response rates were 74% and 51% after two months of LMV and ADV treatment respectively (P = 0.026). The time taken to HBV DNA negative conversion and to HBV DNA response were both delayed in ADV treatment compared with LMV. Conclusion: The antiviral efficacy of ADV in LMV-resistant patients is slower and less potent than that with LMV in nucleoside-naïve patients during the early course of treatment.

Original languageEnglish
Pages (from-to)4072-4079
Number of pages8
JournalWorld Journal of Gastroenterology
Volume13
Issue number30
Publication statusPublished - 2007 Aug 14

Fingerprint

Lamivudine
Chronic Hepatitis B
Antiviral Agents
DNA
Therapeutics
Nucleosides
adefovir dipivoxil
adefovir
Serum

Keywords

  • Adefovir
  • Chronic hepatitis B
  • Lamivudine
  • Treatment efficacy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{d1a75cb45ef4439fb9a030a1e9cb4856,
title = "Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance",
abstract = "Aim: To compare the antiviral efficacy of adefovir (ADV) in lamivudine (LMV)-resistant patients with LMV treatment in nucleoside-na{\"i}ve patients, using serum samples collected sequentially during the course of treatment progressing from LMV to ADV. Methods: Forty-four patients with chronic hepatitis B (CHB) were included. The patients were initially treated with LMV and then switched to ADV when LMV resistance developed. Antiviral efficacy was assessed by measuring the following: reduction in serum HBV DNA from baseline, HBV DNA negative conversion (defined as HBV DNA being undectable by the hybridization assay), and HBV DNA response (either HBV DNA level 105 copies/mL or a 2 log10 reduction from baseline HBV DNA level). Results: After two and six months of treatment, HBV DNA reduction was greater with LMV compared to ADV treatment (P = 0.021). HBV DNA negative conversion rates were 64{\%} and 27{\%} after one month of LMV and ADV treatment respectively (P = 0.001). Similarly, HBV DNA response rates were 74{\%} and 51{\%} after two months of LMV and ADV treatment respectively (P = 0.026). The time taken to HBV DNA negative conversion and to HBV DNA response were both delayed in ADV treatment compared with LMV. Conclusion: The antiviral efficacy of ADV in LMV-resistant patients is slower and less potent than that with LMV in nucleoside-na{\"i}ve patients during the early course of treatment.",
keywords = "Adefovir, Chronic hepatitis B, Lamivudine, Treatment efficacy",
author = "Seo, {Yeon Seok} and Kim, {Ji Hoon} and Yeon, {Jong Eun} and Park, {Jong Jae} and Kim, {Jae Seon} and Byun, {Kwan Soo} and Young-Tae Bak and Lee, {Chang Hong}",
year = "2007",
month = "8",
day = "14",
language = "English",
volume = "13",
pages = "4072--4079",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "30",

}

TY - JOUR

T1 - Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance

AU - Seo, Yeon Seok

AU - Kim, Ji Hoon

AU - Yeon, Jong Eun

AU - Park, Jong Jae

AU - Kim, Jae Seon

AU - Byun, Kwan Soo

AU - Bak, Young-Tae

AU - Lee, Chang Hong

PY - 2007/8/14

Y1 - 2007/8/14

N2 - Aim: To compare the antiviral efficacy of adefovir (ADV) in lamivudine (LMV)-resistant patients with LMV treatment in nucleoside-naïve patients, using serum samples collected sequentially during the course of treatment progressing from LMV to ADV. Methods: Forty-four patients with chronic hepatitis B (CHB) were included. The patients were initially treated with LMV and then switched to ADV when LMV resistance developed. Antiviral efficacy was assessed by measuring the following: reduction in serum HBV DNA from baseline, HBV DNA negative conversion (defined as HBV DNA being undectable by the hybridization assay), and HBV DNA response (either HBV DNA level 105 copies/mL or a 2 log10 reduction from baseline HBV DNA level). Results: After two and six months of treatment, HBV DNA reduction was greater with LMV compared to ADV treatment (P = 0.021). HBV DNA negative conversion rates were 64% and 27% after one month of LMV and ADV treatment respectively (P = 0.001). Similarly, HBV DNA response rates were 74% and 51% after two months of LMV and ADV treatment respectively (P = 0.026). The time taken to HBV DNA negative conversion and to HBV DNA response were both delayed in ADV treatment compared with LMV. Conclusion: The antiviral efficacy of ADV in LMV-resistant patients is slower and less potent than that with LMV in nucleoside-naïve patients during the early course of treatment.

AB - Aim: To compare the antiviral efficacy of adefovir (ADV) in lamivudine (LMV)-resistant patients with LMV treatment in nucleoside-naïve patients, using serum samples collected sequentially during the course of treatment progressing from LMV to ADV. Methods: Forty-four patients with chronic hepatitis B (CHB) were included. The patients were initially treated with LMV and then switched to ADV when LMV resistance developed. Antiviral efficacy was assessed by measuring the following: reduction in serum HBV DNA from baseline, HBV DNA negative conversion (defined as HBV DNA being undectable by the hybridization assay), and HBV DNA response (either HBV DNA level 105 copies/mL or a 2 log10 reduction from baseline HBV DNA level). Results: After two and six months of treatment, HBV DNA reduction was greater with LMV compared to ADV treatment (P = 0.021). HBV DNA negative conversion rates were 64% and 27% after one month of LMV and ADV treatment respectively (P = 0.001). Similarly, HBV DNA response rates were 74% and 51% after two months of LMV and ADV treatment respectively (P = 0.026). The time taken to HBV DNA negative conversion and to HBV DNA response were both delayed in ADV treatment compared with LMV. Conclusion: The antiviral efficacy of ADV in LMV-resistant patients is slower and less potent than that with LMV in nucleoside-naïve patients during the early course of treatment.

KW - Adefovir

KW - Chronic hepatitis B

KW - Lamivudine

KW - Treatment efficacy

UR - http://www.scopus.com/inward/record.url?scp=34548240700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548240700&partnerID=8YFLogxK

M3 - Article

C2 - 17696224

AN - SCOPUS:34548240700

VL - 13

SP - 4072

EP - 4079

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 30

ER -